Patents by Inventor Benjamin Engelhardt

Benjamin Engelhardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS WITH AN ANTI HUMAN CD39 ANTIBODY, AN ANTI HUMAN PD-1 ANTIBODY, AND CHEMOTHERAPY IN GASTRIC CANCER
    Publication number: 20250188165
    Abstract: Provided herein are dosing and combination therapies with a CD39 antibody, a PD-1 antibody, and FOLFOX or CAPOX in gastric cancer. Immune checkpoint inhibitors have revolutionized the cancer treatment paradigm. These agents modulate the tumor microenvironment or other aspects of the immune system to overcome the immune suppression that a tumor elicits on the host immune system. Anti-PD-1/programmed cell death ligand-1 (PD-L1) agents target immunosuppressive pathways and have been shown to be beneficial in numerous tumor types.
    Type: Application
    Filed: March 6, 2023
    Publication date: June 12, 2025
    Inventors: Joyson Karakunnel, Achim Moesta, Courtney Beers, Alana Lerner, Benjamin Engelhardt, Akshanth R. Polepally, Daniel E.H. Afar, Peter S. Moon
  • COMBINATIONS WITH AN ANTI HUMAN CD39 ANTIBODY, AN ANTI HUMAN PD-1 ANTIBODY, AND CHEMOTHERAPY IN GASTRIC CANCER
    Publication number: 20240150487
    Abstract: Provided herein are dosing and combination therapies with a CD39 antibody, a PD-1 antibody, and FOLFOX or CAPDX in gastric cancer.
    Type: Application
    Filed: March 6, 2023
    Publication date: May 9, 2024
    Inventors: Joyson Karakunnel, Achim Moesta, Courtney Beers, Alana Lerner, Benjamin Engelhardt, Akshanth R. Polepally, Daniel E.H. Afar, Peter S. Moon